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Abstract:  
Background: Epithelial ovarian cancer has a poor prognosis, mostly due to its late diagnosis and to the development of drug resistance 
after a first platinum-based regimen. The presence of a specific population of “cancer stem cells” could be responsible of the relapse of 
the tumor, and of the development of resistance to therapy. For this reason, it would be important to specifically target this subpopulation 
of tumor cells in order to increase the response to therapy.  
Method: We screened a chemical compound library assembled during the COST CM1106 action to search for compound classes active 
in targeting ovarian stem cells. We here report the results of the high-throughput screening assay in two ovarian cancer stem cells and 
the differentiated cells derived from them. 
Results and conclusion: Interestingly there were compounds active only on stem cells, only on differentiated cells and compounds 
active on both cell populations. Even if these data need to be validated in ad hoc dose response cytotoxic experiments, the ongoing 
analysis of the compound structures will open up to mechanistic drug studies to select compounds able to improve the prognosis of 
ovarian cancer patients. 
 
Keywords: Cancer stem cell, chemical compounds library, oncology screening, high-throughput screening, ovarian cancer, therapy 
resistance. 
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1. INTRODUCTION 
 Epithelial ovarian carcinoma (EOC) is the sixth most 
common cancer in both European and North America women 
and the leading cause of death from gynaecological 
malignancies [1, 2]. The lack of effective screening tests 
accounts for an advanced disease diagnosis. In addition, after 
an initial response to chemotherapy (generally a combination 
of platinum salts and taxanes), patients relapse with a chemo-
resistant disease. Resistance to therapy has multifactorial 
causes [3]. Among them, the existence of a cancer stem cells 
(CSCs) population was put forward some years ago [4, 5]. The 
“cancer stem cell” hypothesis states that tumours are 
hierarchically organized as their normal tissues counterpart, 
and that their long term maintenance is attributable to the 
ability of CSCs to self-renew indefinitely [5]. The cumulating 
data suggest that CSCs or cells with stem-like properties are 
much more resistant to chemotherapy than cells comprising 
the bulky tumour [6]. Moreover, it has been shown that 
transcriptional signatures associated to CSCs is predictive of 
poor overall patients survival, and experimental and clinical 
evidence suggests that CSCs survive to commonly used 
anticancer treatments (both cytotoxic and targeted therapy), 
implying that these cells are possibly responsible for disease 
recurrence and treatment resistance [7-9]. For these reasons 
the identification and the targeting of CSCs has been an 
important research area in oncology. 
An unambiguous phenotype for ovarian CSC is still 
lacking, even if some hypothesis on the origin of ovarian 
cancer has been recently proposed. Indeed, recent studies 
suggest that the most high-grade serous ovarian cancer 
(~80%) originates in the ovarian fimbriae [10, 11]. 
Specifically, the hypothesis states that a stem cell in the 
fimbria could accumulate DNA damage, which may result in 
the development of a “p53 signature”, followed by 
development of a serous tubal intraepithelial carcinoma 
(STIC). These STIC lesions may shed from papillary tufts, 
and may implant on the surface of the ovary. The exposure to 
a stromal niche and autocrine signals may induce the 
development of high-grade serous carcinoma (HGSC) 
carcinogenesis and metastasis. It has been reported that the 
fimbria stem cells are characterized as c-Kit+, tubulin β4+, 
paired box 8+, and CD44+ cells, and are able to form spheres 
containing all the different fimbriae cells (ciliated, secretory 
and basally located cells) [11]. The first description of stem 
cells in ovarian cancer was reported in the ascites of an 
ovarian patient, derived from a single clone which could grow 
as spheres in culture, and could be sequentially propagated in 
tumours over several generations [12]. The characterization of 
ovarian CSCs was also studied by the detection of specific 
markers (i.e. CD133, CD117, CD24, and CD44), by the 
presence of the side population (SP, a particular phenotype 
that depends on the ability of the cells to extrude drugs by 
membrane pumps), or by the ALDH activity [13-16]. Alvero 
et al.,  were able to isolate CD44+ cells from primary cell 
lines, from tumour and ovarian ascites, and these could 
produce tumours in mice [17]. Gao et al reported the CD24 as 
a putative CSC marker in ovarian cancer, as few as 5,000 
CD24+ cells were able to form tumours in nude mice [18]. We 
could isolate two ovarian cancer stem-like cells (#83 and 
#110) from fresh tumour samples, that were able to grow as 
spheres in culture [19]. Specifically, we demonstrated that 
these cells were able to form tumour when as few as one cell 
was injected in immune-deficient nude mice, they were able 
to self-renew, and to differentiate in vitro. We showed that 
these cells were more resistant to drugs usually used in the 
treatment of ovarian cancer (such as, cisplatin, paclitaxel), and 
to other anti-tumour drugs (such as, etoposide), than their 
more differentiated counterpart in vitro. Moreover, these 
spheres cultures present a mesenchymal phenotype, and 
recently different groups, including ours, have published that 
genes involved in epithelial-mesenchymal transition (EMT) 
were associated with overall or progression free survival, 
suggesting also contribution of EMT to the resistance 
mechanisms [19].  
With this background, in order to find potential new 
agents in ovarian cancer, we screened the chemical library 
gathered in the frame of the COST action CM1106 
(http://www.cost.eu/COST_Actions/cmst/CM1106) on the 
survival of our two ovarian cancer cell lines (#83-SC and 
#110-SC) and in the differentiated cells derived from them 
(#83-DC and #110-DC). 
 
2. EXPERIMENTAL 
 Cell cultures. Low adherence cell conditions. #83 
and #110 were grow in low adherence flasks (Corning) under 
stem-cell conditions as reported [19] serum-free DMEM/F12 
medium supplemented with 5 µg/mL insulin (Sigma), 20 
ng/mL human recombinant epidermal growth factor (EGF, 
Peprotech), 10 ng/mL basic fibroblastic growth factor (bFGF, 
Peprotech) and B27 Supplement (Gibco).  
Differentiated cell conditions. Cells from dissociated 
spheres were cultured in differentiating conditions 
(RPMI/F12 medium 1:1 supplemented with 10% fetal bovine 
serum) for one week. These conditions have been 
demonstrated to induce cell differentiation [19]. After one 
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week of culture, differentiated cells and those derived from 
dissociated spheres were plated in 384 well plates at a 
concentration of 12,500 cells/ml.  
Chemical library. The chemical compound library was 
comprised by 576 compounds dissolved in DMSO and stored 
at -20°C in pre-prepared aliquots ready to use. It included 
synthetic compounds and natural products extracted from 
marine organisms and from plants, as well as reference 
compounds and not yet published compounds. The library is 
characterized by an extreme diversity: from glucosides, 
nucleosides to pseudo peptides.  
Drug treatment. 96 hours after seeding, cells were 
treated at the dose of 20µM. The high-throughput screening 
was performed with an automated liquid handling system 
(JANUSTM, PerkinElmer), connected to a WinPREP for Janus 
software, with which it was possible to set up ad hoc programs 
for the screening (e.g. seeding and drug treatment). Cell 
survival was analyzed by the MTS assay system (Promega) 72 
hrs after treatment. MTS reagent (5 μL) was added to each 
well and after a constant incubation time for all the plates 
absorbance was acquired using a plate reader (Infinite M200, 
TECAN). Each sample (control and treated) was done 
triplicate. Beyond the chemical compounds included in the 
library, cells were treated also with cisplatin, as an internal 
positive control of cell toxicity in each plate. Cisplatin was 
found to be more active in differentiated cells  than in stem 
cells (3% versus 25% of %Ctr), as already reported [19]. 
Data analysis. Survival data were elaborated and were 
considered active if they induced a maximum of 20% cell 
survival compounds over control/untreated cells (%CTR), 
calculated as: [Abs treated/Abs no-treated cells*100]). 
Positive compound (cisplatinum at the IC80 dose of 32µM) 
were included in the screening platform. Vehicle control was 
included in the screening (DMSO at the same concentration 
used in the screening). The t-test analysis revealed a statistical 
significance with a p value< 0.0001 for all the active 
compounds. The power of the high-throughput screening was 
evaluated by calculating the Z-score value, as previously 
described [20]. The average Z’ score for the overall screening 
was 0.69.  
 
 
 
3. RESULTS and DISCUSSIONS 
Under the COST Action CM1106 a library of 1200 
compounds coming from different research groups was 
assembled. The library is made up of synthetic and natural 
compounds, whose structure and mechanism of action is 
under evaluation (data not shown). We used 576 of them for 
our screening. The compounds were tested in the two ovarian 
enriched stem cell cultures #83 and #110, and in their 
differentiated counterpart. This setting has already been 
demonstrated to possibly discriminate compounds active 
(%Ctr ≤20% and 10 %) on stem cells and on the more 
differentiated counterpart [19] (Supplementary Table 1).  
A number of compounds was found to be very active in 
both #83 and #110 cells (Fig. 1). In particular, 29 and 34 
compounds out of 576 were found to be cytotoxic (Ctr%≤ 10 
and 20%) in both SC and DC of #83 and #110 cell lines, 
respectively 4.5% and 6.0% (Fig. 1, panel A, Supplementary 
Tables 2 and 3).  Interestingly, a number of compounds were 
found to be active in both SCs (n=33) or in both DCs (n=44) 
of the #83 and #110 cell lines (Fig. 1, panel B, Supplementary 
Tables 4 and 5), suggesting the possibility to specifically 
target the former cellular subtype.  
In addition, among the compounds contained in the 
CM1106 library, we observed that some were targeting only 
the stem-like cells (Table 1) and some only the differentiated 
cells (Table 2), while other compounds were active on both 
cell states (Table 3). The chemical structures of all the active 
compounds are reported in Fig. (2). 
 
Table 1. Compounds found to be active only in SC cells.  
 
The %Ctr value for each compound is reported.  
 
Among the most active compounds targeting stem cells, we 
found compounds with different mechanism of action. 
Sirtuins are NAD(+)-dependent class III histone deacetylases 
regulating important metabolic pathways in prokaryotes and 
eukaryotes and are involved in many biological processes, 
including cancer [21]. NJW5 is a sirtuin inhibitor whose 
discovery and validation of SIRT2 inhibitors was based on 
tenovin-6 by a ¹H-NMR method to assess deacetylase activity 
[22, 23]. We observed that compounds RN246 (%Ctr of 
17.7% and 10.3% in #83 and #110 SC, respectively) and 
RN422 (%Ctr of 4.41% and -6.2% in #83 and #110 SC, 
respectively) displayed good activity, while in both the DCs 
we observed a very low cytotoxic activity. The syntheses of 
these compounds have been recently published [24, 25]. The 
more efficient compounds able to kill 90% (%Ctr≤10%) of the 
stem like cells were the tyrosine kinases inhibitors: sunitinib 
(platelet derived growth factor receptor- PDGFR, vascular 
endothelial growth factor receptor-VEGFR), erlotinib (against 
the EGFR kinase) and dasatinib (against the bcrl/abl kinase), 
while we observed no activity with imatinib (against ABL, 
KIT, PDGFR kinases). This differential activity is difficult to 
explain and could be due to the different role of the kinases in 
the growth of SC and requires further work. 
# Compound  #83 SC  #110 SC Putative mechanism of action
1 SAHA 
Vorinostat
16,00 -5,08 HDAC inhibitor
2 NJW5 -13,65 -12,57 Sirtuin inhibitor
3 CSA4 16,82 6,51 Tubulin destabilizer
4 RN 246 17,73 10,30 HDAC inhibitor
5 RN 422 4,41 -6,17 HDAC inhibitor
6 Sunitinib 9,80 2,61 Tyrosine kinase
7 JK20 (R004) 14,07 6,23 Tubulin destabilizer
8 KO191 (R005) 19,53 0,45 Tubulin destabilizer
9 BB20 -8,39 -7,08 Unknown
10 Chaetocyne -3,25 -2,63 HMT ihnibitor
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Table 2 shows the compounds specifically active on 
differentiated cells.  Again, clinically used cytotoxic drugs 
were preferentially active on DC (taxol and camptothecin). 
Perezone (compound VR7), a CDC25 phosphatase inhibitor 
is a natural compound recently isolated from the soft coral 
Pseudopterogorgia rigida, and was found more active on DC 
than on SC.  Phosphatases represent a group of proteins 
involved in different pathological processes, including cancer 
[26], and recent evidence suggest that their inhibition could 
have an antitumor effect [27, 28]. 
Table 3 summarizes the compounds that were active on 
both SC and DC cells. Again, most of these compounds are 
new compounds that are under characterization. 
 
Table 2. Compounds found to be active in only DC cells.  
 
The %Ctr value for each compound is reported. 
 
Table 3. Compounds found to be active in both #83 and #110 
SC and DC cells.  
 
The %Ctr value for each compound is reported. 
 
The screening of this library in our experimental setting 
allowed us to find that some compound families were active 
on stem cells, while others were indistinctly active on both 
states. Apart from the cytotoxic agents and tyrosine kinases 
inhibitors, drugs modulating the gene expression have been 
clearly found to be active on both cell types. Epigenetic 
alterations through modulation of the level of acetylation and 
methylation of DNA have been shown to exert antitumor 
effect. Recently, combinations of 5-AzaC or 5-AzaDC with 
HDACi have been approved by FDA and  the European 
Medicines Agency (EMA) for treatment of hematologic 
malignancies [29]. It was reported that not only the 
combination 5-AzaC plus butyrate targets CSCs [30], but that 
the same combination markedly reduced CSC abundance and 
increased the overall survival in a mouse model, differentially 
regulating genes that are involved in tumor growth [31]. Many 
of the compounds we found active were epigenetic 
compounds and potentially active in both stem cells and 
differentiated cells foreseeing the idea that to treat cancer we 
likely need compounds with different mechanism of action 
(epigenetic and cytotoxic), and able to kill tumor cells with 
different biological state (stem cell versus differentiated). 
The fact that compounds with different specificity were 
found corroborates the notion that tumors are made up of 
different subset of cells with not only specific biological 
properties but also with different pharmacological 
sensitivities [32]. We found compounds active on each cell 
type or active of both. In our opinion, the most interesting are 
both the ones acting on SC, that we envisage need be used in 
conjunction with compounds active on bulky tumor cells, and 
the ones acting on both DC and SC. 
4. CONCLUSION 
We successfully screened part of the chemical 
compound library (576 compounds) gathered in the frame of 
the COST action CM1106 using the recently isolated ovarian 
cancer stem cell enriched cultures and the differentiated non-
tumorigenic cells derived from them. We found compounds 
active only against cancer stem cells, only against 
differentiated cells and compounds active against both SC and 
DC cells. From the available information the active drugs 
belong to different chemical classes, and their mechanisms of 
action on stem cells are under study. 
These data need to be validated in ad hoc dose-response 
cytotoxic experiments, mechanistic studies, and the 
specificity of the cytotoxic activity investigated by using a 
larger panel of cancer cell lines. Analysis of the compound 
structures is underway opening up to mechanistic drug studies 
to possibly select compounds able to improve the prognosis 
of ovarian cancer patients. 
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# Compound  #83 DC #110 DC Putative mechanism of action
11 PB-NODB -8,07 -7,82 HDAC inhibitor
12 LOM 621 -4,08 -2,35 Unknown
13 RC 960 -5,50 -2,13 HDAC inhibitor
14 RC 714 -3,57 -4,30 HDAC inhibitor
15 Taxol 18,03 7,15 Tubulin destabilizer
16 Camptothecin 15,06 14,34 Topoisomerase I inhibitor
17 BB15 14,25 15,42 Unknown
18 VR7 -9,50 -2,86 CDC25 inhibitor
19 VR10 19,51 12,86 Unknown
20 ADTA240 -3,96 0,61 Unknown
21 ADMR231 8,02 11,54 Unknown
22 Entinostat 14,04 1,31 HDAC inhibitor
23 ELTE-CSA2 15,94 10,30 Unknown
24 MTA-BSz-1 -11,97 -3,48 Unknown
25 MTA-BSz-3 -12,77 -10,48 Unknown
26 MTA-BSz-4 -12,14 -8,58 Unknown
27 ELTE-MZs-3 13,50 0,23 Unknown
28 ELTE-MZs-8 16,29 7,26 Unknown
29 ELTE-MZs-10 2,56 7,08 Unknown
# Compound  #83 SC  #83 DC  #110 SC #110 DC Putative mechanism of action
30 RB241 -8,53 6,99 -15,06 -0,56 Base analogue
31 5 Aza-Cytidine 11,04 10,54 3,01 13,73 DNA demethylating agents
32 AB-040 -7,39 -7,19 -10,06 -9,16 Base analogue
33 Tenovin 6 -1,79 2,46 -1,00 -2,28 Sirt inhibitor
34 PA-BU -1,20 -5,85 -5,76 -6,22 Apoptosis inducer
35 6MeOH 15,44 -4,76 -5,44 -5,46 Apoptosis inducer
36 RS3301 17,20 18,41 4,71 1,19 Tubulin destabilizer
37 RS3883 19,10 17,63 10,43 15,87 Tubulin destabilizer
38 COLChicine 15,78 17,49 6,08 3,70 Tubulin destabilizer
39 LOM 612 -2,18 -4,08 -6,96 -2,88 Foxo inhibitor
40 RC 173 15,79 -1,80 -1,37 1,31 Atypical retinoid 
41 Thio-colchicine 10,07 9,64 17,07 5,95 Tubulin inhibitor
42 Podophyllotoxin 19,74 5,30 10,74 -0,42 Antimitotic
43 LY-83.583 -10,84 -11,08 -5,22 -15,07 Guanyl cyclase inhibitor
44 BB3 14,09 14,98 12,42 -1,08 Apoptosis inducer
45 BB6 6,39 -9,08 -6,10 -5,51 Apoptosis inducer
46 BB7 -10,05 -4,70 -5,63 -11,92 Unknown
47 MIC1 -1,53 -2,88 5,03 5,25 Unknown
48 MTA-BSz-2 7,48 -10,18 15,40 -5,13 Unknown
49 MTA-BSz-5 6,91 -10,90 9,31 -2,03 Unknown
50 ELTE-MZs-2 18,19 -5,63 15,35 -3,07 Unknown
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